<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01651442</url>
  </required_header>
  <id_info>
    <org_study_id>R01MH091053-01</org_study_id>
    <secondary_id>R01MH091075</secondary_id>
    <nct_id>NCT01651442</nct_id>
  </id_info>
  <brief_title>Sequenced Therapies for Comorbid and Primary Insomnias</brief_title>
  <official_title>Sequenced Therapies for Comorbid and Primary Insomnias</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jack Edinger, PhD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Jewish Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic insomnia is a prevalent disorder associated with increased health care costs,&#xD;
      impaired functioning, and an increased risk for developing serious psychiatric disorders.&#xD;
      Cognitive-behavioral therapies (CBTs) and benzodiazepine receptor agonist (BzRA) medications&#xD;
      are the most widely supported approaches for insomnia management. Unfortunately, few studies&#xD;
      have compared the psychological/behavioral therapies and BzRAs for insomnia treatment.&#xD;
      Moreover, insomnia treatment studies have been limited by small, highly screened study&#xD;
      samples, fixed-dose and fixed-agent pharmacotherapy strategies that do not represent usual&#xD;
      adjustable dosing practices, relatively short follow-up intervals, and reliance on&#xD;
      self-report or polysomnographic (PSG) sleep parameters as outcomes, rather than on more&#xD;
      clinically relevant indicators of remission. Finally, studies have yet to test the benefits&#xD;
      of treatment sequencing for those who do not respond to initial their insomnia therapy. This&#xD;
      multi-site project will address these limitations. Two study sites will enroll a total of 224&#xD;
      participants who meet broad criteria for a chronic insomnia disorder, and a sizeable portion&#xD;
      (60%) of this sample will have insomnia occurring comorbid to a psychiatric disorder.&#xD;
      Participants will be evaluated with clinical assessments and PSG, and then will be randomly&#xD;
      assigned to first-stage therapy with an easy-to-administer behavioral insomnia therapy (BT)&#xD;
      or zolpidem (most widely prescribed BzRA). Centrally trained therapists will administer&#xD;
      therapies according to manualized, albeit flexible, treatment algorithms. Initial outcomes&#xD;
      will be assessed after 6 weeks, and treatment remitters will be followed for the next 12&#xD;
      months on maintenance therapy. Those not achieving remission will be offered re-randomization&#xD;
      to a second, 6-week treatment involving pharmacotherapy (zolpidem or trazodone) or&#xD;
      psychological therapy (BT or cognitive therapy-CT). All participants will be re-evaluated 12&#xD;
      weeks after protocol initiation, and at 3-, 6-, 9-, and 12-month follow-ups while continuing&#xD;
      their final treatment. Insomnia remission, defined categorically as a score &lt; 8 on the&#xD;
      Insomnia Severity Index, will serve as the primary outcome for treatment comparisons.&#xD;
      Secondary outcomes will include sleep diary and PSG sleep measures; subjective ratings of&#xD;
      sleep and daytime function; adverse events; dropout rates; and treatment acceptability. Our&#xD;
      over-arching goal is to obtain new information that aids in the development of clinical&#xD;
      guidelines for managing insomnia sufferers with and without comorbid psychiatric conditions.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 1, 2012</start_date>
  <completion_date type="Actual">March 1, 2017</completion_date>
  <primary_completion_date type="Actual">March 1, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of Participants Who Met Remission as Measured by the Insomnia Severity Index</measure>
    <time_frame>6 weeks, 12 weeks, 3 months, 6 months, 9 months &amp; 12 months</time_frame>
    <description>The Insomnia Severity Index (ISI) is a self-report questionnaire assessing the nature, severity, and impact of insomnia. Remission is determined to be a score less-than 8.</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">211</enrollment>
  <condition>Insomnia Comorbid to Psychiatric Disorder</condition>
  <condition>Primary Insomnia</condition>
  <arm_group>
    <arm_group_label>Non-drug Sleep Therapy 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sleep Medication 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-drug Sleep Therapy 2 Following Non-drug Sleep Therapy 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sleep Medication 2 Following Sleep Medication 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-drug Sleep Therapy 1 Following Sleep Medication 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sleep Medication 1 Following Non-drug Sleep Therapy 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Behavioral Insomnia Therapy</intervention_name>
    <description>Sleep hygiene, stimulus control, and sleep restriction presented in four sessions.</description>
    <arm_group_label>Non-drug Sleep Therapy 1</arm_group_label>
    <arm_group_label>Non-drug Sleep Therapy 1 Following Sleep Medication 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zolpidem</intervention_name>
    <description>5mg or 10mg</description>
    <arm_group_label>Sleep Medication 1</arm_group_label>
    <arm_group_label>Sleep Medication 1 Following Non-drug Sleep Therapy 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trazodone</intervention_name>
    <description>50mg to 150mg</description>
    <arm_group_label>Sleep Medication 2 Following Sleep Medication 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Cognitive Therapy</intervention_name>
    <description>Cognitive restructuring, constructive worry, behavioral experiments presented in four sessions.</description>
    <arm_group_label>Non-drug Sleep Therapy 2 Following Non-drug Sleep Therapy 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  a complaint of persistent (i.e., &gt; 1 month) difficulties initiating or maintaining&#xD;
             sleep despite adequate opportunity for sleep;&#xD;
&#xD;
          -  a sleep onset latency or wake time after sleep onset &gt; 30 minutes 3 or more nights per&#xD;
             week during two weeks sleep diary monitoring;&#xD;
&#xD;
          -  an Insomnia Severity Index (ISI) score &gt; 10 indicating at least &quot;mild&quot; insomnia; and&#xD;
&#xD;
          -  a score ≥ 2 on either the interference or distress item of the screening ISI,&#xD;
             indicating the insomnia causes significant distress or impairment in social,&#xD;
             occupational, or other areas of functioning. These criteria represent those provided&#xD;
             in the DSM-IV-TR87, Research Diagnostic Criteria3 and the International Classification&#xD;
             of Sleep Disorders4, and will ensure a sample with clinically relevant insomnia.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Exclusion criteria will be minimal to retain a broadly representative sample that includes&#xD;
        patients with primary and insomnia comorbid to a psychiatric disorder. Likewise,&#xD;
        individuals with a comorbid medical condition will be excluded only if the medical&#xD;
        condition is life-threatening or would contra-indicate using study medications. Exclusion&#xD;
        criteria are&#xD;
&#xD;
          -  an untreated psychiatric disorder (e.g., major depression) as these conditions have&#xD;
             specific treatments and it would be inappropriate not to offer those treatments;&#xD;
&#xD;
          -  a lifetime diagnosis of any psychotic or bipolar disorder as sleep restriction and&#xD;
             medications for insomnia may precipitate mania and hallucinations;&#xD;
&#xD;
          -  an imminent risk for suicide;&#xD;
&#xD;
          -  alcohol or drug abuse within the past year, since BzRAs are cross-tolerant with&#xD;
             alcohol;&#xD;
&#xD;
          -  terminal or progressive physical illness (e.g., cancer, COPD), or neurological&#xD;
             degenerative disease (e.g., dementia);&#xD;
&#xD;
          -  current use of medications known to cause insomnia (e.g., steroids);&#xD;
&#xD;
          -  sleep apnea (apnea/hypopnea index &gt; 15), restless legs syndrome, periodic limb&#xD;
             movement during sleep (PLMS with arousal &gt; 15 per hour), or a circadian rhythm sleep&#xD;
             disorder (e.g., advanced sleep phase syndrome);&#xD;
&#xD;
          -  habitual bedtimes later than 2:00 AM or rising times later than 10:00 AM;&#xD;
&#xD;
          -  consuming &gt; 2 alcoholic beverages per day on a regular basis.&#xD;
&#xD;
        Individuals using sleep-aids (prescribed or over-the-counter) will be included if they are&#xD;
        willing and able to discontinue medications at least 2 weeks before baseline assessment.&#xD;
        Participants using alcohol as a sleep aid or alcohol after 7:00pm on a regular basis will&#xD;
        be required to discontinue this practice at least two weeks prior to baseline assessment.&#xD;
        Individuals using psychotropic medications (e.g., anxiolytics, antidepressants) will not be&#xD;
        automatically excluded from the study. Those on stable dosages (for at least three months)&#xD;
        of SSRI or SNRI medications and who show at least partial remission (via SCID) from their&#xD;
        mood or anxiety disorder will be accepted in the study if they meet the selection criteria&#xD;
        above. Patients using TCAs, MAOIs, or atypical antidepressants will be excluded even if in&#xD;
        remission as the effects of these medications on sleep might confound interpretation of the&#xD;
        findings. We will impose similar standards for those with MDD, dysthymia, panic disorder,&#xD;
        phobia, and GAD. We realize that some decisions about enrollment may not always be easy to&#xD;
        make, but we will rely on all available data and a consensus approach to guide our clinical&#xD;
        decision making process&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jack Edinger, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Jewish Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Charles Morin, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universite Laval</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Jewish Health</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Université Laval</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>June 26, 2012</study_first_submitted>
  <study_first_submitted_qc>July 24, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 27, 2012</study_first_posted>
  <results_first_submitted>May 31, 2019</results_first_submitted>
  <results_first_submitted_qc>August 9, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">August 28, 2019</results_first_posted>
  <last_update_submitted>March 4, 2021</last_update_submitted>
  <last_update_submitted_qc>March 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>National Jewish Health</investigator_affiliation>
    <investigator_full_name>Jack Edinger, PhD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
    <mesh_term>Problem Behavior</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zolpidem</mesh_term>
    <mesh_term>Trazodone</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 25, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/42/NCT01651442/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Non-drug Sleep Therapy 1</title>
          <description>Behavioral Insomnia Therapy: Sleep hygiene, stimulus control, and sleep restriction presented in four sessions.</description>
        </group>
        <group group_id="P2">
          <title>Sleep Medication 1</title>
          <description>Zolpidem: 5mg or 10mg</description>
        </group>
        <group group_id="P3">
          <title>Non-drug Sleep Therapy 2 Following Non-drug Sleep Therapy 1</title>
          <description>Cognitive Therapy: Cognitive restructuring, constructive worry, behavioral experiments presented in four sessions.</description>
        </group>
        <group group_id="P4">
          <title>Sleep Medication 2 Following Sleep Medication 1</title>
          <description>Trazodone: 50mg to 150mg</description>
        </group>
        <group group_id="P5">
          <title>Non-drug Sleep Therapy 1 Following Sleep Medication 1</title>
          <description>Behavioral Insomnia Therapy: Sleep hygiene, stimulus control, and sleep restriction presented in four sessions.</description>
        </group>
        <group group_id="P6">
          <title>Sleep Medication 1 Following Non-drug Sleep Therapy 1</title>
          <description>Zolpidem: 5mg or 10mg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Phase I Treatment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="104"/>
                <participants group_id="P2" count="107"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="88"/>
                <participants group_id="P2" count="80"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="27"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Phase II Treatment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="27"/>
                <participants group_id="P4" count="27"/>
                <participants group_id="P5" count="27"/>
                <participants group_id="P6" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="25"/>
                <participants group_id="P4" count="15"/>
                <participants group_id="P5" count="21"/>
                <participants group_id="P6" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Non-drug Sleep Therapy 1</title>
          <description>Behavioral Insomnia Therapy: Sleep hygiene, stimulus control, and sleep restriction presented in four sessions.</description>
        </group>
        <group group_id="B2">
          <title>Sleep Medication 1</title>
          <description>Zolpidem: 5mg or 10mg</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="104"/>
            <count group_id="B2" value="107"/>
            <count group_id="B3" value="211"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.9" spread="14.4"/>
                    <measurement group_id="B2" value="45.4" spread="15.5"/>
                    <measurement group_id="B3" value="45.6" spread="14.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="132"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="94"/>
                    <measurement group_id="B2" value="93"/>
                    <measurement group_id="B3" value="187"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent of Participants Who Met Remission as Measured by the Insomnia Severity Index</title>
        <description>The Insomnia Severity Index (ISI) is a self-report questionnaire assessing the nature, severity, and impact of insomnia. Remission is determined to be a score less-than 8.</description>
        <time_frame>6 weeks, 12 weeks, 3 months, 6 months, 9 months &amp; 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Non-drug Sleep Therapy 1</title>
            <description>Behavioral Insomnia Therapy: Sleep hygiene, stimulus control, and sleep restriction presented in four sessions.</description>
          </group>
          <group group_id="O2">
            <title>Sleep Medication 1</title>
            <description>Zolpidem: 5mg or 10mg</description>
          </group>
          <group group_id="O3">
            <title>Sleep Medication 1 Plus Non-drug Sleep Therapy 1</title>
            <description>Zolpidem Plus Behavioral Therapy</description>
          </group>
          <group group_id="O4">
            <title>Sleep Medication 1 Plus Sleep Medication 2</title>
            <description>Zolpidem Plus Trazodone</description>
          </group>
          <group group_id="O5">
            <title>Non-drug Sleep Therapy 1 Plus Non-drug Sleep Therapy 1</title>
            <description>Behavioral Therapy Plus Cognitive Therapy</description>
          </group>
          <group group_id="O6">
            <title>Non-drug Sleep Therapy 1 Plus Sleep Medication 1</title>
            <description>Behavioral Therapy Plus Zolpidem</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants Who Met Remission as Measured by the Insomnia Severity Index</title>
          <description>The Insomnia Severity Index (ISI) is a self-report questionnaire assessing the nature, severity, and impact of insomnia. Remission is determined to be a score less-than 8.</description>
          <units>percent remitted</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="83"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="27"/>
                <count group_id="O5" value="27"/>
                <count group_id="O6" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.00"/>
                    <measurement group_id="O2" value="34.94"/>
                    <measurement group_id="O3" value="37.04"/>
                    <measurement group_id="O4" value="48.15"/>
                    <measurement group_id="O5" value="44.44"/>
                    <measurement group_id="O6" value="55.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected during the period from March 1, 2012 to July 1, 2017. Adverse Events were monitored in participants during the entirety of their participation, up to approximately 17 months for each participant.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Non-drug Sleep Therapy 1</title>
          <description>Behavioral Insomnia Therapy: Sleep hygiene, stimulus control, and sleep restriction presented in four sessions.</description>
        </group>
        <group group_id="E2">
          <title>Sleep Medication 1</title>
          <description>Zolpidem: 5mg or 10mg</description>
        </group>
        <group group_id="E3">
          <title>Non-drug Sleep Therapy 2</title>
          <description>Cognitive Therapy: Cognitive restructuring, constructive worry, behavioral experiments presented in four sessions.</description>
        </group>
        <group group_id="E4">
          <title>Sleep Medication 2</title>
          <description>Trazodone: 50mg to 150mg</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Bryan Simmons</name_or_title>
      <organization>National Jewish Health</organization>
      <phone>303-398-1850</phone>
      <email>simmonsb@njhealth.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

